Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
Blood Cells, Molecules, and Diseases, Volume 50, No. 4, Year 2013
Notification
URL copied to clipboard!
Description
Cardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subsequent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction (LVEF) offers an accurate and reproducible method for heart function evaluation. These findings suggest a reduction in LVEF ≥ 7%, over time, determined by 2-D echocardiography, may be considered a strong predictive tool for the detection of thalassemia major patients with increased risk of cardiac death. The reduction of LVEF ≥ 7% had higher (84.76%) predictive value. Finally, Kaplan-Meier survival curves of thalassemia major patients with LVEF ≥ 7% showed a statistically significant decreased probability of survival for heart disease (p = 0.0022). However, because of limitations related to the study design, such findings should be confirmed in a large long-term prospective clinical trial. © 2012 Elsevier Inc.
Authors & Co-Authors
Maggio, Aurelio M.
Unknown Affiliation
Vitrano, Angela
Unknown Affiliation
Calvaruso, Giuseppina
Unknown Affiliation
Barone, Rita
Unknown Affiliation
Rigano, Paolo
Unknown Affiliation
Mancuso, Luigi
Unknown Affiliation
Cuccia, Liana
Unknown Affiliation
Capra, Marcello
Unknown Affiliation
Pitrolo, Lorella
Unknown Affiliation
Prossomariti, Luciano
Unknown Affiliation
Filosa, Aldo
Unknown Affiliation
Caruso, Vincenzo
Unknown Affiliation
Gerardi, Calogera
Unknown Affiliation
Campisi, Saveria
Unknown Affiliation
Cianciulli, P.
Unknown Affiliation
Elefteriou, Androulla
Unknown Affiliation
Angastiniotis, Michael A.
Unknown Affiliation
Hamza, Hala Salah El Din
Unknown Affiliation
Telfer, Paul T.
Unknown Affiliation
Walker, Malcolm
Unknown Affiliation
Phrommintikul, A.
Unknown Affiliation
Chattipakorn, Nipon
Unknown Affiliation
Statistics
Citations: 22
Authors: 22
Affiliations: 18
Identifiers
Doi:
10.1016/j.bcmd.2012.12.002
ISSN:
10799796
e-ISSN:
10960961
Research Areas
Noncommunicable Diseases
Study Design
Cohort Study